Editorial
T-cell responses to small cell lung cancer: the immune system and the tumor are two sides of the same coin
Translational Lung Cancer Research
2023;
12
(8)
:1658-1660
.
(30 August 2023)
Expert Consensus
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease
Translational Lung Cancer Research
2023;
12
(8)
:1661-1701
.
(30 August 2023)
Original Article
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
Translational Lung Cancer Research
2023;
12
(8)
:1702-1716
.
(30 August 2023)
The effectiveness of surgical treatment of lung cancer in Polish academic and nonacademic centers
Translational Lung Cancer Research
2023;
12
(8)
:1717-1727
.
(30 August 2023)
Augmented reality navigation-guided intraoperative pulmonary nodule localization: a pilot study
Translational Lung Cancer Research
2023;
12
(8)
:1728-1737
.
(30 August 2023)
KMT2C expression and DNA homologous recombination repair factors in lung cancers with a high-grade fetal adenocarcinoma component
Translational Lung Cancer Research
2023;
12
(8)
:1738-1751
.
(30 August 2023)
Patterns and outcome of unplanned care in lung cancer patients: an observational study in a medical oncology department
Translational Lung Cancer Research
2023;
12
(8)
:1752-1765
.
(30 August 2023)
Construction and validation of a novel ferroptosis-related prognostic signature for lung adenocarcinoma
Translational Lung Cancer Research
2023;
12
(8)
:1766-1781
.
(30 August 2023)
Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
Translational Lung Cancer Research
2023;
12
(8)
:1782-1789
.
(30 August 2023)
A CT-based radiomics integrated model for discriminating pulmonary cryptococcosis granuloma from lung adenocarcinoma—a diagnostic test
Translational Lung Cancer Research
2023;
12
(8)
:1790-1801
.
(30 August 2023)
Study Protocol
A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study)
Translational Lung Cancer Research
2023;
12
(8)
:1802-1806
.
(30 August 2023)
Editorial Commentary
Improved understanding of NSCLC immunotherapy response mechanisms from single-cell analysis
Translational Lung Cancer Research
2023;
12
(8)
:1807-1811
.
(30 August 2023)
Building on success: key takeaways from the 5-year update of the KEYNOTE-407 study
Translational Lung Cancer Research
2023;
12
(8)
:1812-1815
.
(30 August 2023)
Single-cell insights into the dynamic tumor microenvironment changes during immunotherapy of non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(8)
:1816-1821
.
(30 August 2023)
Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system
Translational Lung Cancer Research
2023;
12
(8)
:1822-1825
.
(30 August 2023)
Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?
Translational Lung Cancer Research
2023;
12
(8)
:1826-1829
.
(30 August 2023)
KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(8)
:1830-1833
.
(30 August 2023)
